-- The NEW Official Alizyme Thread! --

I agree with Fidra about the potential for a 400p price during 2006 on conclusion deal(s) and (I would add) further cash from Takeda. Afterall, a deal for Cetilistat or Renzapride has the potential to transform the balance sheet and allow the introduction of new products into the pipeline. However, there remains uncertainty as to whether any deals will be delivered (intentionally or not) and I still consider they will be taken-over.

Incidentally, through the period 2003-5, posters here have reported Tim McCarthy as saying the share price is about to be transformed upwards, but nothing has ever happened, infact quite the opposite.

AZM's approximate recent year end closing prices, as follows:

End 2003: 170p
End 2004: 140p
End 2005: 125p

In addition, after announcing on the 27/9/2004 deals for Renzapride and COLAL-PRED could potentially be concluded within 6 months, AZM subsequently did just the opposite and staged a dilutive share issue in Spring 2005; and the deals have still not been concluded 15 months later.

"Building shareholder value", more like destroying shareholder value; and making some questionably positive forward looking statements imo. Consequently, they have probably lost a lot of investor goodwill imo.

Large pharmas must know the above makes AZM vulnerable to a take-over and impatient investors would potentially take the first offer that comes along, which could be during 2006 imo.

P.S.
It looks like they may have failed to meet yet another of their own deadlines, in this case, to commence recruitment into EU PIII COLAL-PRED acute before the end of 2005! Let us hope this possible delay is because they intend to first conclude a deal for COLAL-PRED any day now.